Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Status:
Withdrawn
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 1/2 Study of VELCADE (bortezomib), Nipent (pentostatin), and Rituxan
(rituximab) (VNR) in Subjects with Relapsed Follicular, Marginal Zone, and Mantle Cell
Lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Louisiana State University Health Sciences Center Shreveport